{
    "Clinical Trial ID": "NCT02162719",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ipatasertib and Paclitaxel",
        "  Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
        "INTERVENTION 2: ",
        "  Placebo and Paclitaxel",
        "  Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Histologically documented triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and is not amenable to resection with curative intent",
        "  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "  Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen, required prior to randomization",
        "  Measurable disease, according to the RECIST v1.1",
        "  Adequate hematologic and organ function within 14 days before the first study treatment",
        "  For female participants of childbearing potential, agreement (by both participant and partner) to use an effective form of contraception for the duration of the study and for 6 months after last dose of study treatment",
        "Exclusion Criteria:",
        "  Any previous therapy, including chemotherapy or hormonal or targeted therapy, for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy and/or radiation treatment for locally advanced triple negative adenocarcinoma, provided all treatments were completed greater than or equal to (>/=) 6 months prior to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with curative intent",
        "  Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1",
        "  Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor (ER) positive, or progesterone receptor (PR) positive breast cancer",
        "  Previous therapy with Akt, PI3K, and/or mTOR inhibitors",
        "  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study",
        "  Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression Free Survival (PFS)",
        "  PFS was defined as the time from randomization to the first occurrence of disease progression, as determined by investigator review of tumor assessments by RECIST, v1.1 or death on study (<=30 days after the last dose of study treatment regimen) from any cause, whichever occurred first.",
        "  Time frame: Baseline up to 30 days after the last dose of study drug administration (Clinical Cut Off Date: 07 June 2016)",
        "Results 1: ",
        "  Arm/Group Title: Ipatasertib and Paclitaxel",
        "  Arm/Group Description: Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with ipatasertib 400 mg, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
        "  Overall Number of Participants Analyzed: 62",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: Months  6.18        (4.57 to 7.33)",
        "Results 2: ",
        "  Arm/Group Title: Placebo and Paclitaxel",
        "  Arm/Group Description: Participants randomised to receive paclitaxel 80 mg/m^2, intravenously on Days 1, 8, and 15 along with placebo matching ipatasertib, orally, once daily from Days 1-21 in each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.",
        "  Overall Number of Participants Analyzed: 62",
        "  Median (90% Confidence Interval)",
        "  Unit of Measure: Months  4.93        (3.58 to 5.36)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 18/61 (29.51%)",
        "  Pancytopenia 0/61 (0.00%)",
        "  Febrile Neutropenia 2/61 (3.28%)",
        "  Constipation 0/61 (0.00%)",
        "  Diarrhoea 3/61 (4.92%)",
        "  Nausea 1/61 (1.64%)",
        "  Pancreatitis 1/61 (1.64%)",
        "  Death 0/61 (0.00%)",
        "  Pyrexia 2/61 (3.28%)",
        "  Cholestasis 0/61 (0.00%)",
        "  Atypical Pneumonia 1/61 (1.64%)",
        "  Cystitis 0/61 (0.00%)",
        "  Gastroenteritis 0/61 (0.00%)",
        "  Influenza 0/61 (0.00%)",
        "Adverse Events 2:",
        "  Total: 12/62 (19.35%)",
        "  Pancytopenia 1/62 (1.61%)",
        "  Febrile Neutropenia 0/62 (0.00%)",
        "  Constipation 1/62 (1.61%)",
        "  Diarrhoea 0/62 (0.00%)",
        "  Nausea 0/62 (0.00%)",
        "  Pancreatitis 0/62 (0.00%)",
        "  Death 1/62 (1.61%)",
        "  Pyrexia 1/62 (1.61%)",
        "  Cholestasis 1/62 (1.61%)",
        "  Atypical Pneumonia 0/62 (0.00%)",
        "  Cystitis 1/62 (1.61%)",
        "  Gastroenteritis 1/62 (1.61%)",
        "  Influenza 1/62 (1.61%)"
    ]
}